RS56371B1 - Supstituisana tetrahidrokarbazol i karbazol karboksamid jedinjenja koja se koriste kao inhibitori kinaze - Google Patents

Supstituisana tetrahidrokarbazol i karbazol karboksamid jedinjenja koja se koriste kao inhibitori kinaze

Info

Publication number
RS56371B1
RS56371B1 RS20170904A RSP20170904A RS56371B1 RS 56371 B1 RS56371 B1 RS 56371B1 RS 20170904 A RS20170904 A RS 20170904A RS P20170904 A RSP20170904 A RS P20170904A RS 56371 B1 RS56371 B1 RS 56371B1
Authority
RS
Serbia
Prior art keywords
kinase inhibitors
compounds useful
carboxamide compounds
carbazole carboxamide
substituted tetrahydrocarbazole
Prior art date
Application number
RS20170904A
Other languages
English (en)
Inventor
Joseph A Tino
Anurag S Srivastava
Soo Sung Ko
Michael A Galella
Charles M Langevine
George V Delucca
Qingjie Liu
Douglas G Batt
Scott Hunter Watterson
Qing Shi
Myra Beaudoin Bertrand
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of RS56371B1 publication Critical patent/RS56371B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20170904A 2013-06-25 2014-06-25 Supstituisana tetrahidrokarbazol i karbazol karboksamid jedinjenja koja se koriste kao inhibitori kinaze RS56371B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361839141P 2013-06-25 2013-06-25
PCT/US2014/043978 WO2014210085A1 (en) 2013-06-25 2014-06-25 Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
EP14740094.9A EP3013814B1 (en) 2013-06-25 2014-06-25 Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
RS56371B1 true RS56371B1 (sr) 2017-12-29

Family

ID=51210830

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170904A RS56371B1 (sr) 2013-06-25 2014-06-25 Supstituisana tetrahidrokarbazol i karbazol karboksamid jedinjenja koja se koriste kao inhibitori kinaze

Country Status (31)

Country Link
US (6) US9334290B2 (sr)
EP (1) EP3013814B1 (sr)
JP (1) JP6353529B2 (sr)
KR (1) KR102346508B1 (sr)
CN (1) CN105358546B (sr)
AR (1) AR096721A1 (sr)
AU (1) AU2014302548B2 (sr)
BR (1) BR112015030723A8 (sr)
CA (1) CA2916500A1 (sr)
CL (1) CL2015003635A1 (sr)
CY (1) CY1119371T1 (sr)
DK (1) DK3013814T3 (sr)
EA (1) EA026729B1 (sr)
ES (1) ES2636652T3 (sr)
HK (1) HK1223359A1 (sr)
HR (1) HRP20171031T1 (sr)
HU (1) HUE034460T2 (sr)
IL (1) IL243296B (sr)
LT (1) LT3013814T (sr)
MA (1) MA38648B1 (sr)
MY (1) MY176631A (sr)
PE (1) PE20160519A1 (sr)
PH (1) PH12015502630A1 (sr)
PL (1) PL3013814T3 (sr)
PT (1) PT3013814T (sr)
RS (1) RS56371B1 (sr)
SI (1) SI3013814T1 (sr)
TN (1) TN2015000529A1 (sr)
TW (1) TWI648272B (sr)
UY (1) UY35625A (sr)
WO (1) WO2014210085A1 (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014210087A1 (en) 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
EP3209652B1 (en) 2014-10-24 2020-04-15 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
SG11201703188QA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Indole carboxamides compounds useful as kinase inhibitors
CN107074804B (zh) 2014-10-24 2020-02-18 百时美施贵宝公司 咔唑衍生物
CA3029482A1 (en) 2016-07-01 2018-01-04 Brio Device Llc Intubation stylet with video feed
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
WO2018118830A1 (en) 2016-12-20 2018-06-28 Bristol-Myers Squibb Company Process for preparing tetrahydrocarbazole carboxamide compound
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Btk阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および/または治療剤
KR102612513B1 (ko) 2018-07-31 2023-12-12 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
AU2023220628A1 (en) * 2022-02-15 2024-05-23 F. Hoffmann-La Roche Ag Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006053121A2 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2006064355A2 (en) 2004-12-17 2006-06-22 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
EP1924557A2 (en) * 2005-09-16 2008-05-28 Serenex, Inc. Carbazole derivatives
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2006316322B2 (en) 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
AU2007297221B2 (en) 2006-09-11 2012-11-08 Mylan Laboratories Limited Dibenzofuran derivatives as inhibitors of PDE-4 and PDE-10
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ,インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
WO2009075830A1 (en) 2007-12-13 2009-06-18 Merck & Co., Inc. Inhibitors of janus kinases
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
EP2391602B1 (en) * 2008-12-19 2013-12-04 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
ES2562183T3 (es) 2010-03-26 2016-03-02 Merck Patent Gmbh Benzonaftiridinaminas como inhibidores de la autotaxina
US8685969B2 (en) * 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
EP2640729B1 (en) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibitors of hiv replication
EP2709997B1 (en) 2011-05-17 2016-06-29 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy

Also Published As

Publication number Publication date
PH12015502630A1 (en) 2016-03-07
HRP20171031T1 (hr) 2017-10-06
US20160194338A1 (en) 2016-07-07
EP3013814B1 (en) 2017-06-14
SI3013814T1 (sl) 2017-08-31
KR102346508B1 (ko) 2022-01-03
US20180079758A1 (en) 2018-03-22
EA201592287A1 (ru) 2016-06-30
MY176631A (en) 2020-08-19
PL3013814T3 (pl) 2017-11-30
US10435415B2 (en) 2019-10-08
CA2916500A1 (en) 2014-12-31
TWI648272B (zh) 2019-01-21
WO2014210085A1 (en) 2014-12-31
CY1119371T1 (el) 2018-02-14
US20140378475A1 (en) 2014-12-25
US20190023719A1 (en) 2019-01-24
ES2636652T3 (es) 2017-10-06
CN105358546A (zh) 2016-02-24
EP3013814A1 (en) 2016-05-04
IL243296B (en) 2018-05-31
US9850258B2 (en) 2017-12-26
TW201536774A (zh) 2015-10-01
HK1223359A1 (zh) 2017-07-28
CL2015003635A1 (es) 2016-07-29
PE20160519A1 (es) 2016-05-21
CN105358546B (zh) 2017-10-31
MA38648A1 (fr) 2017-09-29
DK3013814T3 (en) 2017-09-25
JP2016523907A (ja) 2016-08-12
US20170283438A1 (en) 2017-10-05
MA38648B1 (fr) 2018-06-29
US20190382416A1 (en) 2019-12-19
US9334290B2 (en) 2016-05-10
BR112015030723A8 (pt) 2020-01-07
KR20160022889A (ko) 2016-03-02
JP6353529B2 (ja) 2018-07-04
WO2014210085A9 (en) 2015-12-23
AU2014302548A1 (en) 2016-02-11
AU2014302548B2 (en) 2018-05-10
EA026729B1 (ru) 2017-05-31
BR112015030723A2 (pt) 2017-07-25
LT3013814T (lt) 2017-08-10
UY35625A (es) 2014-12-31
TN2015000529A1 (en) 2017-04-06
PT3013814T (pt) 2017-08-10
AR096721A1 (es) 2016-01-27
HUE034460T2 (en) 2018-02-28
US10106559B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
ME03740B (me) Jedinjenja indol karboksamida korisna kao inhibitori kinaze
HK1253099A1 (zh) 作為激酶抑制劑的雜環酰胺
HK1223359A1 (zh) 用作激酶抑制劑的經取代的四氫咔唑及咔唑甲酰胺化合物
IL243295A0 (en) Carbazole carboxamide compounds are useful as kinase inhibitors